Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

BACKGROUND: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Ching, Travers, Duncan, Megan E., Newman-Eerkes, Tera, McWhorter, Mollie M. E., Tracy, Jeffrey M., Steen, Michelle S., Brown, Ryan P., Venkatasubbarao, Srivatsa, Akers, Nicholas K., Vignali, Marissa, Moorhead, Martin E., Watson, Drew, Emerson, Ryan O., Mann, Tobias P., Cimler, B. Melina, Swatkowski, Pamela L., Kirsch, Ilan R., Sang, Charles, Robins, Harlan S., Howie, Bryan, Sherwood, Anna
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325652/
https://ncbi.nlm.nih.gov/pubmed/32605647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07077-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados